GSK, after pushing past midphase fail, ends development of otilimab in COVID-19

GlaxoSmithKline is stopping development of otilimab in COVID-19, reacting to the failure of the drug in phase 2 and the progress of its anti-SARS-CoV-2 antibody by pulling the plug on the program. Development of otilimab in rheumatoid arthritis is continuing.